Drug intelligence / Profile preview

18F-FMPP

Development stage
Phase 3
Lead developer
Peking Union Medical College Hospital
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

18F-FMPP is a novel radiopharmaceutical used as a positron emission tomography (PET) imaging agent. It is primarily developed as a myocardial perfusion imaging (MPI) tracer targeting mitochondrial complex I in cardiac tissue. Preclinical and clinical studies indicate that 18F-FMPP demonstrates high and uniform uptake in the heart with low background activity in the liver, making it suitable for assessing myocardial perfusion and ischemia. Additionally, research has explored its use as a PET tracer for cyclooxygenase-2 (COX-2) expression imaging due to its specific binding properties observed in COX-2 positive cells. The compound is administered intravenously and is not currently approved for clinical use outside of trials[1][2][4].

Other names
FMPP[18F]fluoromethyl-pyrimidine-pyrazole
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on 18F-FMPP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-FMPP.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call